Advances in the treatment of diabetic renal disease: Focus on losartan

Current Medical Research and Opinion

Volumn 20, Issue 3, 2004, Pages 333-340

  Rayner, Brian ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

AII receptor blockers; Angiotensin II; Diabetes; End stage renal disease (ESRD); Losartan

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHYMASE; CILAZAPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; POTASSIUM; RAMIPRIL; RENIN; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASOCONSTRICTOR AGENT;

BLOOD PRESSURE REGULATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG UTILIZATION; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FAILURE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; LOSARTAN; MODELS, ANIMAL; PROTEINURIA; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; RISK;

EID: 1542720651     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125003107     Document Type: Review

References (56)

1. US renal data system. USRDS 1999 annual data report. Bethesda MD: National Institute of Diabetes and Digestive and Kidney Disease 1999
2. Valderrabano F, Berthoux FC, Jones EH, Mehls O. Report on management of renal failure in Europe, XXV, 1994 end stage renal disease and dialysis report. The EDTA-ERA Registry. European Dialysis and Transplant Association-European Renal Association. Nephrol Dial Transplant 1996;11(Suppl 1);2-21
3. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001;12:2753-8
4. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-32
5. American Diabetes Association. Diabetic Nephropathy. Diabetes Care 2003;26(Suppl 1), S94-S98
6. Abdi R, Brenner BM. The nephropathy of type 2 diabetes: introduction. In: Mogensen CE, ed. Diabetic nephropathy in type 2 diabetes. London: Science Press Ltd, 2003;1-4
7. European Society of Hypertension Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53
8. Hollenberg NK, Osei SY, Lansang MC, Price DA, Fisher ND. Salt intake and non-ACE pathways for intrarenal angiotensin II generation in man. J Renin Angiotensin Aldosterone Syst 2001;2:14-8
9. Osei SY, Price DA, Laffel LM, Lansang MC, Hollenberg NK. Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans. Hypertension 2000;36:122-6
10. Williams B. The renin-angiotensin system and the pathogenesis of diabetic nephropathy. In: Mogensen CE, ed. Diabetic nephropathy in type 2 diabetes. Science Press, 2003:57-70
11. Blantz RC, Gabbai FB. Effect of angiotensin II on glomerular hemodynamics and ultrafiltration coefficient. Kidney Int Suppl 1987;20:S108-S111
12. Gilbert RE, Cox A, Wu LL et al. Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 1998;47:414-22
13. Jaimes EA, Galceran JM, Raij L. Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 1998;54:775-84
14. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354:359-64
15. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87
16. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62
17. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994;271:275-9
18. Remuzzi A, Perico N, Amuchastegui CS et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993;4:40-9
19. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992;90:766-71
20. Holdaas H, Hartmann A, Berg KJ, Lund K, Fauchald P. Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol Dial Transplant 1998;13:3096-102
21. Toto R, Shultz P, Raij L et al. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension 1998;31:684-91
22. Praga M, Andrade CF, Luño J et al. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant 2003;18:1-8
23. Park HC, Xu ZG, Choi S et al. Effect of losartan and amlodipine on proteinuria and transforming growth factor-β1 in patients with IgA nephropathy. Nephrol Dial Transplant 2003;18:1115-21
24. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57:601-6
25. Zandbergen AA, Baggen MG, Lamberts SW, Bootsma AH, de Zeeuw D, Ouwendijk RJ. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. Ann Intern Med 2003;139:90-6
26. Chan JC, Critchley JA, Tomlinson B, Chan TY, Cockram CS. Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997;17:72-80
27. Lozano JV, Llisterri JL, Aznar J, Redon J. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001;16(Suppl 1):85-9
28. Esmatjes E, Flores L, Iñigo P, Lario S, Ruilope LM, Campistol JM. Effect of losartan on TGF-β1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 2001;16(Suppl 1):90-3
29. Lacourcière Y, Bélanger A, Godin C et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000;58:762-9
30. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
31. Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
32. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10
33. Lindholm LH, Dahlof B, Edelman JM et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003;362:619-20
34. Lindholm LH, Ibsen H, Borch-Johnsen K et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002;20:1879-86
35. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-9
36. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
37. Zanella M-T, Ribeiro AB. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. Clin Ther 2002;24:1019-34
38. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4
39. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24
40. Doggrell SA. Class benefits of AT1 anatgonists in type 2 diabetes with nephropathy. Expert Opin Pharmacother 2002;3:625-8
41. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8
42. Sharma K, Eltayeb BO, McGowan TA et al. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999;34:818-23
43. Krämer C, Sunkomat J, Witte J et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002;90:770-6
44. Appel GB, Radhakrishnan J, Avram MM et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003;26:1402-7
45. 2 receptor antagonism but not TXA2 synthase inhibition. J Physiol Pharmacol 2000;51:715-22
46. Li P, Ferrario CM, Brosnihan KB. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1998;32:198-205
47. Jiménez AM, Montón M, García R et al. Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. J Cardiovasc Pharmacol 2001;37:406-12
48. Montón M, Jiménez A, Núñez A et al. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol 2000;35:906-13
49. Núñez A, Gómez J, Zalba LR et al. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan. J Renin Angiotensin Aldosterone Syst 2000;1:175-9
50. Guerra-Cuesta JI, Montón M, Rodriguez-Feo JA et al. Effect of losartan on human platelet activation. J Hypertens 1999;17:447-52
51. Krämer C, Sunkomat J, Witte J et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002;90:770-6
52. Levy PJ, Yunis C, Owen J, Brosnihan KB, Smith R, Ferrario CM. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000;86:1188-92
53. Moser L, Callahan KS, Cheung AK, Stoddard GJ, Munger MA. ACE inhibitor effects on platelet function in stages I-II hypertension. J Cardiovasc Pharmacol 1997;30:461-7
54. Kang DH, Nakagawa T, Feng L et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888-97
55. Wurzner G, Gerster JC, Chiolero A et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001;19:1855-60
56. Ilson BE, Martin DE, Boike SC, Jorkasky DK. The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. J Clin Pharmacol 1998;38:437-41